Working with trusts in the region to implement SecurAcath
Posted: - 16th June 2022
Yorkshire & Humber AHSN have seen success in the spread and adoption of SecurAcath, and across the region, we have seen all 13 hospitals use 26,370 units of the innovation, thereby reducing the need for catheters to be replaced and saving the NHS a significant amount of time and money.
SecurAcath is one of the four innovative products under the 2020/21 Medtech Funding Mandate.
Patients may experience several complications when peripherally inserted central catheters (PICC) are moved or dislodged from their position. This might result in patients experiencing sore skin and discomfort. It may cause delays in therapy or extended treatment plan.
In comparison, SecurAcath can keep a catheter securely in place; it never needs to be changed and does not require sutures or adhesives..
Both patients and staff are really pleased with the product, with one patient saying:
“I have been really impressed by how the PICC line and SecurAcath has transformed my experience as nurses always had problems getting a cannula in.
I find it very comfortable to the point that I forget I have it and occasionally catch it. I have never had any problems with it moving position, my skin has been sore at times, caused by my treatment but the SecurAcath has never made my skin sore. I am really glad I have it” Metastatic bowel cancer patient on fortnightly treatment that requires a PICC line.
Find out more about how we are supporting the spread and adoption of the MedTech Funding Mandate products in our Impact Report